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Abstract: BACKGROUND AND PURPOSE Recent observations linked coronavirus disease 2019 (COVID-
19) to thromboembolic complications possibly mediated by increased blood coagulability and inflamma-
tory endothelial impairment. We aimed to define the risk of acute stroke in patients with severe and
non-severe COVID-19. METHODS We performed an observational, multicenter cohort study in four par-
ticipating hospitals in Saxony, Germany to characterize consecutive patients with laboratory-confirmed
COVID-19 who experienced acute stroke during hospitalization. Furthermore, we conducted a system-
atic review using PubMed/MEDLINE, Embase, Cochrane Library and bibliographies of identified papers
following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines including data
from observational studies of acute stroke in COVID-19 patients. Data were extracted by two independent
reviewers and pooled with multicenter data to calculate risk ratios (RRs) and 95% confidence intervals
(95% CIs) for acute stroke related to COVID-19 severity using a random-effects model. Between-study
heterogeneity was assessed using Cochran’s Q and I2 statistics. International Prospective Register of
Systematic Reviews registration number: CRD42020187194. RESULTS Of 165 patients hospitalized for
COVID-19 (49.1% males, median age = 67 years [57-79 years], 72.1% severe or critical) included in the
multicenter study, overall stroke rate was 4.2% (95% CI: 1.9-8.7). Systematic literature search identified
two observational studies involving 576 patients that were eligible for meta-analysis. Amongst 741 pooled
COVID-19 patients, overall stroke rate was 2.9% (95% CI: 1.9-4.5). Risk of acute stroke was increased for
patients with severe compared to non-severe COVID-19 (RR = 4.18, 95% CI: 1.7-10.25; P = 0.002) with
no evidence of heterogeneity (I2 = 0%, P = 0.82). CONCLUSIONS Synthesized analysis of data from
our multicenter study and previously published cohorts indicates that severity of COVID-19 is associated
with an increased risk of acute stroke.
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Background and purpose: Recent observations linked coronavirus disease 2019
(COVID-19) to thromboembolic complications possibly mediated by increased
blood coagulability and inflammatory endothelial impairment. We aimed to
define the risk of acute stroke in patients with severe and non-severe COVID-19.
Methods: We performed an observational, multicenter cohort study in four
participating hospitals in Saxony, Germany to characterize consecutive
patients with laboratory-confirmed COVID-19 who experienced acute stroke
during hospitalization. Furthermore, we conducted a systematic review using
PubMed/MEDLINE, Embase, Cochrane Library and bibliographies of identi-
fied papers following Preferred Reporting Items for Systematic Reviews and
Meta-Analyses guidelines including data from observational studies of acute
stroke in COVID-19 patients. Data were extracted by two independent review-
ers and pooled with multicenter data to calculate risk ratios (RRs) and 95%
confidence intervals (95% CIs) for acute stroke related to COVID-19 severity
using a random-effects model. Between-study heterogeneity was assessed using
Cochran’s Q and I2 statistics. International Prospective Register of Systematic
Reviews registration number: CRD42020187194.
Results: Of 165 patients hospitalized for COVID-19 (49.1% males, median
age = 67 years [57–79 years], 72.1% severe or critical) included in the multicen-
ter study, overall stroke rate was 4.2% (95% CI: 1.9–8.7). Systematic literature
search identified two observational studies involving 576 patients that were eli-
gible for meta-analysis. Amongst 741 pooled COVID-19 patients, overall
stroke rate was 2.9% (95% CI: 1.9–4.5). Risk of acute stroke was increased
for patients with severe compared to non-severe COVID-19 (RR = 4.18, 95%
CI: 1.7–10.25; P = 0.002) with no evidence of heterogeneity (I2 = 0%,
P = 0.82).
Conclusions: Synthesized analysis of data from our multicenter study and pre-
viously published cohorts indicates that severity of COVID-19 is associated
with an increased risk of acute stroke.
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Infection with severe acute respiratory syndrome coron-
avirus 2 (SARS-CoV-2) has been linked to altered
blood coagulability and increased risk of thromboem-
bolic complications including venous and arterial
embolism possibly mediated by systemic inflammatory
injury of the endothelium, platelet activation and stasis
[1,2]. Whilst high rates of pulmonary embolism and
deep venous thrombosis have been reported in multiple
coronavirus disease 2019 (COVID-19) cohorts, it
remains poorly understood whether the disease might
also manifest with acute stroke [3,4]. A retrospective
observational study from Wuhan, China found cere-
brovascular diseases during hospitalization in 5.7% of
patients with severe COVID-19 and in 0.8% of patients
with a non-severe course of the disease [5]. A possible
pathophysiological link between COVID-19 and acute
stroke has been further supported by individual case
reports and small case series [6–8].
To explore a possible association between infection with
SARS-CoV-2 and acute stroke we studied four cohorts of
patients hospitalized for COVID-19 for occurrence of
acute stroke, and pooled multicenter data with published
data from the literature in a comprehensive meta-analysis.
Methods
Multicenter study
We included consecutive patients ≥18 years old with
laboratory-confirmed diagnosis of COVID-19 who
had been admitted to four participating hospitals with
neurological departments including accredited stroke
units (University Hospital Carl Gustav Carus Dres-
den, Klinikum Chemnitz gGmbH, Elblandklinikum
Meissen, St€adtisches Klinikum Dresden) in Saxony,
Germany between 1 March 2020 and 30 April 2020 in
our retrospective multicenter study. Locations of par-
ticipating hospitals are illustrated in Fig. 1. Labora-
tory confirmation of SARS-CoV-2 was performed
using real-time reverse transcription polymerase chain
reaction (RT-PCR) assays (RealStar SARS-CoV-2
RT-PCR Kit RUO; Altona Diagnostics, Hamburg,
Germany; Allplex 2019-nCoV Assay; Seegene, Seoul,
Republic of Korea; GeneFinder COVID-19 Plus Rea-
lAmp; Osang Healtcare, Gyeonggi-do, Republic of
Korea; BD SARS-CoV-2 Reagents for BD MAX Sys-
tem; BD Life Sciences, Sparks, NV, USA) from nasal
or oropharyngeal swab.
This study was approved by the institutional review
board (IRB) of Technical University Dresden (IRB num-
ber BO-EK-154042020). Due to the observational nature
of the study design, informed consent was waived.
We obtained data on age, sex and vascular comor-
bidities including past history of cerebrovascular dis-
ease and venous thrombotic event, neurological
symptoms during hospitalization not attributed to
stroke and laboratory data relevant to inflammation
and coagulation. Furthermore, we evaluated clinical
course of COVID-19 using the classification by the
National Health Commission guidelines on the Diag-
nosis and Treatment of COVID-19 [9]. Disease stages
were categorized as ‘mild’ (mild symptoms absent
Figure 1 Location of participating sites in Saxony (color-coded map), Germany (grey map), with rates of confirmed infections with
severe acute respiratory syndrome coronavirus 2 in Saxony based on epidemiological data provided by the Robert Koch Institute as of
30 April 2020 (www.rki.de/EN/Home/homepage_node.html). UKD, Universit€atsklinikum Carl Gustav Carus Dresden (University
Hospital Carl Gustav Carus Dresden); SKD, St€adtisches Klinikum Dresden. [Colour figure can be viewed at wileyonlinelibrary.com]
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signs of pneumonia on chest imaging), ‘moderate’
(fever, respiratory symptoms with radiologic evidence
of pneumonia), ‘severe’ (respiratory distress with
breathing frequency ≥30 per minute or resting oxygen
saturation ≤93% or growth of pulmonary lesions
>50% within 48 h or oxygenation index ≤300 mmHg),
‘critical’ (respiratory failure necessitating mechanical
ventilation, hemodynamic shock, or any organ failure
requiring intensive care). For data analysis, we dichot-
omized severity categories into ‘severe’ (subsuming
disease stages ‘severe’ and ‘critical’) and ‘non-severe’
(subsuming ‘mild’ and ‘moderate’ stages). We addi-
tionally studied clinical course to categorize phase of
COVID-19 according to Lean European Open Survey
on SARS-CoV-2 Infected Patients (LEOSS) criteria
distinguishing an ‘uncomplicated’ phase characterized
by either absence of symptoms or occurrence of symp-
toms related to upper respiratory tract infection, nau-
sea, emesis, diarrhea or fever from a ‘complicated’
phase defined by necessity of oxygen supplementation,
decreased partial arterial oxygen pressure <70 mmHg
or oxygen saturation <90% at room air, aspartate
aminotransferase or alanine aminotransferase greater
than fivefold upper limit normal, new cardiac arrhyth-
mias, new pericardial effusion >1 cm, new heart fail-
ure with pulmonary edema, congestive hepatopathy or
peripheral edema. Disease phase was classified ‘criti-
cal’ when use of catecholamines was necessary, life-
threatening cardiac arrhythmia occurred, invasive or
non-invasive mechanical ventilation was required, liver
failure was present with international normalized ratio
>1.55, kidney failure with necessity of dialysis
occurred or organ failure was evident by a quick sep-
sis-related Sequential Organ Failure Assessment score
≥2. Lastly, patients were considered to have reached
‘recovery’ phase when they improved by one phase
and showed defervescence [10]. To provide alternative
categorical measures of COVID-19 severity, we
obtained rates of in-hospital death versus survival and
necessity of intensive care versus regular in-patient
care until discharge. Furthermore, we defined ‘any
venous thrombotic event’ including cerebral venous
thrombosis, deep venous thrombosis and pulmonary
embolism during hospitalization as additional severity
outcome.
Acute stroke on admission or during hospitalization
was defined as imaging-confirmed ischaemic stroke,
transient ischaemic attack or intracerebral hemor-
rhage. Patients with COVID-19–related stroke were
characterized for stroke localization, etiology accord-
ing to trial of ORG 10172 in acute stroke treatment
(TOAST) criteria [11] based on available results of
cerebral, cardiac and vascular imaging [brain com-
puted tomography (CT) or magnetic resonance
imaging (MRI) scan, transthoracic echocardiography
with additional transesophageal echocardiography in
those with undetermined etiology/carotid and tran-
scranial ultrasound, long-term electrocardiography].
Furthermore, they were characterized for vessel occlu-
sion, acute treatment, elapsed time from admission to
stroke onset as well as baseline National Institutes of
Health Stroke Scale score.
Literature search and study eligibility
We performed a systematic review and meta-analysis
in accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
recommendations [12]. The protocol was registered
with the International Prospective Register of System-
atic Reviews (PROSPERO; CRD42020187194).
Systematic literature search was undertaken using
electronic databases MEDLINE accessed by PubMed,
Embase and Cochrane Library for all available obser-
vational studies that reported on patients aged
≥18 years with acute stroke during hospitalization for
laboratory-confirmed COVID-19. We also performed
a snowball search in bibliographies of identified full-
text articles and relevant review articles. We applied
search terms ‘COVID-19’, ‘stroke’, ‘cerebrovascular’,
‘cerebrovascular accident’, ‘cerebrovascular disease’,
‘cerebral infarction’, ‘cerebral ischaemia’, ‘intracere-
bral hemorrhage’, ‘transient ischaemic attack’ as well
as their combinations and associated Medical Subject
Headings. Complete search strings as well as the
PRISMA checklist are provided in Appendix S1. Sys-
tematic literature search covered articles from the ear-
liest date available until our last search date 19 May
2020, with no language or other restrictions. Identified
articles were eligible for meta-analysis when all of the
following criteria were met: (i) randomized or non-
randomized observational study reporting on a mini-
mum of five patients aged ≥18 years who have been
hospitalized for COVID-19 confirmed by molecular
RT-PCR, (ii) data available on occurrence of acute
stroke related to COVID-19 hospitalization and (iii)
categorization of severity of COVID-19 according to
study-specific definitions.
Two independent reviewers (T.S. and K.B.) assessed
all identified articles by screening of titles, abstracts
and full texts and resolved any disagreements by con-
sensus. Full-text evaluation was performed where
abstracts did not provide sufficient information for
evaluation of methodology. We contacted correspond-
ing authors of the identified articles if information
was incomplete or any obscurities were present.
Extraction of data from full text articles was under-
taken by two independent reviewers (T.S. and K.B.).
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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All data were inserted into a standardized data extrac-
tion form (Excel; Microsoft, Redmond, WA, USA).
We extracted information on first author, publication
year, study design, sample size, demographic values,
definition of COVID-19 severity and frequency of
index stroke during hospitalization.
Rating of study quality
Study quality of articles included in the meta-analysis
was evaluated using the Oxford Centre for Evidence-
Based Medicine Rating Scale [13]. Two independent
reviewers (T.S. and K.B.) performed quality assess-
ment. Any disagreements were resolved by consensus.
Statistical analysis
Multicenter study
Continuous and non-continuous parameters are pre-
sented as median with interquartile range (IQR) for
skewed data and percentages for proportional data.
Univariate analyses were conducted using v2 test,
Fisher exact test and Mann-Whitney U test, where
applicable. Multivariable logistic regression was
undertaken to determine the predictive value of severe
COVID-19 for occurrence of acute stroke. The final
multivariable model including a priori variables age,
sex, arterial hypertension and diabetes mellitus was
conducted using backward selection procedure with
covariate removal if P value was ≥0.1.
Meta-analysis
Pooled rate of acute stroke was calculated with com-
putation of 95% confidence intervals (95% CIs) using
adjusted Wald method. We computed risk ratios
(RRs) and their corresponding 95% CIs for severe
COVID-19 from the absolute numbers of patients
with and without acute stroke provided by each study.
Studies with a zero cell were subject to continuity cor-
rection of 0.5 [14]. We excluded studies from respec-
tive analyses if two or more zero cell events were
reported. Pooled RRs were computed using the
DerSimonian and Laird random-effects model [15].
Meta-analysis was performed using a composite of
COVID-19 severity subsuming any study-specific defi-
nition. Sensitivity analyses were carried out for
cohorts using comparable definitions for disease sever-
ity. Missing outcome data were handled using a pair-
wise deletion method. We determined heterogeneity
between studies using Cochran’s Q test and I2 statis-
tics, with I2 values of 0% to 40% indicating absent or
low, 30% to 60% moderate, 50% to 90% substantial
and 75% to 100% considerable heterogeneity [16].
Significance level of heterogeneity was set at P < 0.1.
Statistical significance was set at P < 0.05. All sta-
tistical analyses were conducted using the Stata soft-




Our multicenter cohort consisted of 165 patients
(49.1% males, median age = 67 years, IQR 57–79),
with RT-PCR–confirmed COVID-19 who were
admitted to the four participating hospitals between
11 March 2020 and 30 April 2020. At the time of
data acquisition, eight patients were still hospitalized.
An overview of demographic values, comorbidities,
laboratory data and outcomes is shown in Table 1.
In total, seven patients experienced an acute ischae-
mic stroke (n = 4) or a transient ischaemic attack
(n = 3), resulting in an overall rate of 4.2% (95%
CI: 1.9–8.7). Intracerebral hemorrhage or cerebral
venous thrombosis was not observed in the multicen-
ter population. In five of these seven (71.4%)
patients, index stroke was the primary reason for
hospital admission, whereas two (28.6%) patients
experienced an acute stroke following admission for
COVID-19. Six of seven (85.7%) stroke patients
developed a severe course of COVID-19, with neces-
sity of intensive care in three of these cases. One
(14.2%) stroke patient was admitted to the intensive
care unit (ICU) for post-thrombectomy management
rather than COVID-19–related complications. A
detailed description of COVID-19 patients who expe-
rienced an acute stroke is provided in Table 2. Aside
from a tendency toward a higher proportion of past
history of cerebrovascular disease and increase in
serum interleukin-6 level in stroke patients, no differ-
ences in demographics, vascular comorbidities and
laboratory values were present compared to non-
stroke patients (Table 1).
By multivariable backward selection analysis, only
necessity of intensive care remained in the final model
and emerged as independently associated with acute
stroke (OR = 4.69, 95% CI: 1.0–21.9; P = 0.05),
whereas none of the other pre-specified explanatory
variables were predictive of acute stroke.
Systematic review
We retrieved a total of 759 abstracts from electronic
databases and nine from bibliographies of published
literature. After exclusion of duplicates and articles
that did not fulfill eligibility criteria, two studies were
included in the meta-analysis as described in detail in
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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Table 3 [17,18]. The flowchart showing the systematic
screening and selection process is depicted in Fig. 2.
The included studies consisted of multicentric cohorts
from Italy and China, respectively, and were of
descriptive observational design. Severity of COVID-
19 in these studies was defined either clinically accord-
ing to American Thoracic Society guidelines for com-
munity-acquired pneumonia or by necessity of ICU
Table 1 Characteristics of patients from multicenter cohort
COVID-19, n = 165 + Stroke, n = 7  Stroke, n = 158 P
Demographic values
Age, years, median (IQR) 67 (57–79) 72 (71–76) 67 (56–80) 0.3
Men, n (%) 81 (49.1) 3 (42.9) 78 (49.4) 1.0
Past vascular risk factors, n (%)
Arterial hypertension 106 (64.2) 5 (71.4) 101 (63.9) 1.0
Hyperlipidemia 47 (28.5) 2 (28.6) 45 (28.5) 1.0
Diabetes mellitus 51 (30.9) 3 (42.9) 48 (30.4) 0.7
Atrial fibrillation 30 (18.2) 0 (0) 30 (19) 0.4
Tobacco use 22 (13.3) 2 (28.6) 20 (12.7) 0.2
Coronary heart disease 21 (12.7) 1 (14.3) 20 (12.7) 1.0
Cerebrovascular disease 24 (14.6) 3 (42.9) 21 (13.3) 0.06
Ischaemic stroke 19 (11.5) 3 (42.9) 16 (10.1)
Transient ischaemic attack 2 (1.2) 0 (0) 2 (1.3)
Intracerebral hemorrhage 3 (1.8) 0 (0) 3 (1.9)
Venous thrombotic event 10 (6.1) 0 (0) 10 (6.3) 1.0
Cerebral venous thrombosis 0 (0) 0 (0) 0 (0)
Pulmonary embolism 4 (2.4) 0 (0) 4 (2.5)
Deep venous thrombosis 5 (3) 0 (0) 5 (3.2)
Portal vein thrombosis 2 (1.2) 0 (0) 2 (1.3)
Other neurological manifestations, n (%)
Taste impairment 14 (8.5) 0 (0) 14 (8.9) 1.0
Smell impairment 9 (5.5) 0 (0) 9 (5.7) 1.0
Laboratory findings
Lymphocyte count, admission, 9109/l 0.9 (0.7–1.4)a 1.0 (0.8–1.5) 0.9 (0.7–1.3)a 0.6
Lymphocyte count, minimum, 9109/l 0.9 (0.6–1.2)a 0.6 (0.4–0.8) 0.9 (0.6–1.2)a 0.09
Thrombocyte count, admission, 9109/l 185 (148–254) 197 (164–216) 180 (148–256) 0.9
Thrombocyte count, minimum, 9109/l 161 (120–226) 172 (105–197) 160 (121–229) 0.7
D-dimer, admission, mg/l 0.9 (0.5–1.8) 0.8 (0.6–1.5) 0.9 (0.5–1.9) 0.8
D-dimer, maximum, mg/l 1.2 (0.5–3.4) 1.2 (0.6–3.3) 1.2 (0.5–3.4) 0.9
INR, admission 1 (1–1.2) 1 (1–1.1) 1 (1–1.2) 0.6
INR, maximum 1.1 (1–1.4) 1.1 (1.1–1.3) 1.1 (1–1.4) 0.6
C-reactive protein, admission, mg/l 41.5 (10.7–91.5) 50.2 (4.7–92.5) 41.4 (11.1–91.5) 0.8
C-reactive protein, maximum, mg/l 85.1 (34.9–174.8) 157.6 (55.4–191.8) 82.3 (33.1–174.8) 0.3
Interleukin-6 admission, ng/l 30.8 (7.7–74.3)a 46.3 (9.6–53.1) 29.1 (7.7–74.3)a 0.9
Interleukin-6 maximum, ng/l 35.4 (7.3–89.2)a 46.3 (14.1–119) 34 (7.3–85.1)a 0.7
Severity outcomes, n (%)
Disease severity by NHC 0.8
Mild/moderate 46 (27.9) 1 (14.3) 45 (28.5)
Severe 77 (46.7) 4 (57.1) 73 (46.2)
Critical 42 (25.5) 2 (28.6) 40 (25.3)
Stages of disease by LEOSS 0.7
Uncomplicated 43 (26) 1 (14.3) 42 (26.6)
Complicated 77 (46.7) 3 (42.9) 74 (46.8)
Critical 45 (27.3) 3 (42.9) 42 (26.6)
Recovery 101/164 (61.6)b 4 (57.1) 97 (61.8) 1.0
Intensive care treatment 39 (23.6) 4 (57.1) 35 (22.2) 0.06
Any venous thrombotic event 18 (10.9) 1 (14.3) 17 (10.8) 0.6
Cerebral venous thrombosis 0 (0) 0 (0) 0 (0)
Pulmonary embolism 15 (9.1) 1 (14.3) 14 (8.9)
Deep venous thrombosis 11 (6.7) 1 (14.3) 10 (6.3)
In-hospital death 32/157 (20.4)b 2 (20.4) 30 (20) 0.6
INR, international normalized ratio; IQR, interquartile range; LEOSS, Lean European Open Survey on SARS CoV II Infected Patients;
NHC, National Health Commission. aParameters with data available in <70% of the study population. bAccording to available data and
patients discharged at the time of analysis.
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treatment [17,18]. Of 576 laboratory-confirmed
COVID-19 patients (60.9% males, average ages rang-
ing from 53 to 66 years) reported in these studies, 15
patients (2.6%) were reported of having a stroke
related to COVID-19 hospitalization (acute ischaemic
stroke, n = 14; intracerebral hemorrhage, n = 1).
Meta-analysis
Meta-analysis including individual patient data from
our multicenter cohort consisted of 741 laboratory-
confirmed COVID-19 patients (58.3% males, average
age ranging from 52 to 67 years). The overall rate of
stroke was 2.9% (95% CI: 1.9–4.5) in the pooled
COVID-19 population. When dichotomizing by dis-
ease severity, the overall rate of stroke was 5.5%
(95% CI: 3.2–9.1) in patients with severe COVID-19
and 1.7% (95% CI: 0.8–3.3) in those with non-severe
manifestation of the disease.
On quantitative data synthesis, severe COVID-19
was associated with an increased risk of acute stroke
(RR = 4.18, 95% CI: 1.7–10.25; P = 0.002; Fig. 3)
with no evidence of heterogeneity across included
studies (I2 = 0%, P = 0.82). This association remained
unchanged when we solely pooled our multicenter
data with the published Italian cohort that defined
disease severity by necessity of intensive care (RR =
3.72, 95% CI: 1.38–10.0; P = 0.009). When multicen-
ter data were pooled with only the Chinese cohort
defining severity by clinical parameters, we still
observed a tendency toward an increased risk of acute
stroke for severe COVID-19 (RR = 3.97, 95% CI:
0.89–17.63; P = 0.07). There was no between-study
heterogeneity identified in these sensitivity analyses
(I2 = 0%, P = 0.79 and I2 = 0%, P = 0.45, respec-
tively).
Study quality
Studies included in the meta-analysis were consistently
graded as level of evidence 4 according to Oxford
Centre for Evidence-Based Medicine rating scale qual-
ity (Table 3). Publication bias was not assessed due to
the low number of included studies.




















1 65 M AIS Anterior
circulation
Undetermined None None 24 32 Severe/ICU No
2 72 F AIS Posterior
circulation
Undetermined None None 0 — Severe/
general ward
Yes
3 71 F TIA Anterior
circulation
Undetermined None None 0 3 Severe/
general ward
Yes
4 73 F TIA Anterior
circulation
Undetermined None None 0 2 Severe/ICU Yes
5 76 M TIA Posterior
circulation
Undetermined None None 0 — Severe/ICU Yes




None 1 17 Severe/
general ward
No









AIS, acute ischaemic stroke; EVT, endovascular therapy; F, female; ICU, intensive care unit; IVT, intravenous thrombolysis; M, male; MCA,
middle cerebral artery; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischaemic attack. aDiagnosis based on evidence of
atrial fibrillation.
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ICU, intensive care unit. aAccording to quality rating scheme by the Oxford Centre for Evidence-Based Medicine. bMedian (interquartile
range). cAccording to definitions by American Thoracic Society guidelines for community-acquired pneumonia. dMean  standard deviation
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Discussion
The results of this study pooling observational multi-
center data from Germany with published data from
cohorts in Italy and China suggest that patients with
severe course of COVID-19 are at increased risk of
acute ischaemic stroke.
Our investigation has several strengths. We pooled
data of a well-characterized regional multicenter
cohort with published data from geographically dis-
tant cohorts, substantiating generalizability of our
observations. It is noteworthy that each of the regions
providing data ranks amongst the 10 countries most
affected by the pandemic [19]. External validity is fur-
ther supported by consistency of observed severity-de-
pendent stroke rates amongst cohorts and absence of
statistical heterogeneity across studies included in the
quantitative synthesis. All hospitals participating in
our multicenter study had accredited stroke units with
24/7 stroke service available, allowing guideline-based
hyperacute evaluation and treatment of cerebrovascu-
lar diseases. Furthermore, with the exception of two
cases, all patients included in our multicenter analysis
had a cerebral ischaemic event, consistent with the
possibility of an underlying COVID-19–related coagu-
lopathy. There are limitations to our study. Due to
the low number of eligible studies identified from the
literature and absence of statistical heterogeneity, a
meta-regression analysis to elucidate to what extent
the risk association between COVID-19 severity and
acute stroke was independent of covariates was not
considered expedient. Consistently, assessment of pub-
lication bias was not undertaken in consideration of
the limited number of published studies included in
the quantitative synthesis [20]. Furthermore, we can-
not rule out differences in definition of transient
Figure 2 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart illustrating systematic screening and selec-
tion process of published studies.
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Figure 3 Forest plots of stroke risk associated with severe clinical manifestation of COVID-19 for composite severity subsuming all
definitions of severity as reported by included studies (a), as well as for clusters of studies defining severity by grading of clinical
parameters (b) and whether patients required intensive care (c). Individual patient data from German multicenter cohort was evaluated
for severity based on the Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment [9]. CI, confidence interval;
RR, risk ratio. [Colour figure can be viewed at wileyonlinelibrary.com]
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ischaemic attack amongst included studies. We cannot
rule out that a proportion of asymptomatic COVID-
19 in-patients might have remained undetected since
participating hospitals have individually adapted their
testing strategies to the evolving situation after the
outbreak. Lastly, the risk of acute stroke might have
been underestimated in our study in severely ill
patients who required mechanical ventilation, imped-
ing detection of clinical neurological symptoms. We
cannot comment on whether the increased risk of
stroke observed in severe COVID-19 patients is even-
tually different from that in patients with critical ill-
ness resulting from other viral pathogens, as data on
coincident in-hospital strokes in the general popula-
tion are largely lacking.
The exact mechanism whereby COVID-19 may
increase risk of acute stroke is unclear. Previous
research suggested that COVID-19 leads to a hyperco-
agulable state mediated by elevation of prothrombotic
factors, stasis related to immobilization and endothelial
injury either by direct virus invasion of endothelial cells
by mediators of acute systemic inflammation such as
interleukin-6 [21,22]. Interestingly, only one of the
seven stroke patients included in our multicenter study
experienced deep venous thrombosis and pulmonary
embolism during hospitalization, possibly consistent
with a rather primary arterial manifestation of COVID-
19–related coagulopathy in our study population.
Moreover, in five (71.4%) of the seven patients, detailed
cardiovascular assessment has not identified etiology of
stroke constituting a far higher proportion than
observed in stroke populations not infected with
SARS-CoV-2, where diagnosis of stroke of undeter-
mined etiology following TOAST criteria accounts for
approximately one-third of all strokes [23,24]. An
equally high rate of cryptogenic stroke has been found
in a recently published COVID-19 cohort comprising
32 stroke patients from the New York metropolitan
area, of whom 21 (65.6%) had undetermined etiology
[25]. The low yield of standard workup for stroke etiol-
ogy might support the hypothesis of a COVID-19–
specific mechanism mediating acute stroke in these
patients and raises an urgent need for further prospec-
tive investigation including in-depth analysis of stroke
pattern and assessment of the possibility of asymp-
tomatic deep venous thrombosis with paradox embo-
lism. Furthermore, five out of seven patients in our
multicenter cohort presented to the emergency room
with acute stroke prior to developing any respiratory
symptoms, raising the possibility of primary cere-
brovascular manifestation of COVID-19. Consistently,
acute stroke was the reason for admission in almost
half of the SARS-CoV-2–positive stroke patients from
New York [25]. Our pooled analysis comprising
regional multicenter data from the literature showed
that a past history of cerebrovascular disease might be
linked to an increased stroke risk in COVID-19
patients. This underscores the necessity of exploring the
role of cerebrovascular pathology related to SARS-
CoV-2 infection on a pathophysiological level. It is
noteworthy that we do not know what proportion of
stroke patients without any symptoms commonly
attributed to COVID-19 might have been left unde-
tected in our multicenter study. We recently showed in
an observational 4-week single-center study of universal
testing for SARS-CoV-2 that none of the included 116
consecutive code stroke patients tested positive [26].
However, a very low yield of universal testing for
SARS-CoV-2 in stroke patients requires confirmation
in larger study populations.
None of the stroke patients from our multicenter
COVID-19 cohort had neurological symptoms previ-
ously linked to infection with SARS-CoV-2 such as
impairment of taste or smell. In a cohort from the
Wuhan region in China, impaired taste or smell was
noted in 7.1% and 6.3% of patients with non-severe
COVID-19, respectively, but only in 3.4% of those
severely affected by the disease [5]. A large prospective
cohort from Italy found taste or smell dysfunction in
64% of mildly symptomatic patients who tested posi-
tive for SARS-CoV-2 [27]. Taken together, these
observations indicate that cerebrovascular manifesta-
tions might be a consequence of disease-mediated
hypercoagulability rather than of direct cerebral neu-
roinvasion of SARS-CoV-2 as a recently considered
possible cause of disease-related olfactory dysfunction
[28]. Also, the observation that olfactory dysfunction
frequently occurs in mildly affected patients supports
the hypothesis that non-vascular neurological manifes-
tations follow different pathophysiological mecha-
nisms and are less dependent of disease severity than
cerebrovascular manifestations.
Conclusion
Our pooled data from a German multicenter cohort
of COVID-19 patients and published data from the
literature suggests that patients with a severe course
of COVID-19 have an increased risk of acute stroke,
underscoring the necessity of clinical neurological
monitoring in patients infected with SARS-CoV-2 and
warranting further investigation of the underlying
pathophysiology.
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